Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

Rivaroxaban and dabigatran are new oral anticoagulants that specifically inhibit factor Xa and thrombin, respectively. Clinical studies on the prevention and treatment of venous and arterial thromboembolism show promising results. A major disadvantage of these anticoagulants is the absence of an ant...

Full description

Saved in:

Bibliographic Details
Published in:	Circulation (New York, N.Y.) Vol. 124; no. 14; p. 1573
Main Authors:	Eerenberg, Elise S, Kamphuisen, Pieter W, Sijpkens, Meertien K, Meijers, Joost C, Buller, Harry R, Levi, Marcel
Format:	Journal Article
Language:	English
Published:	United States 04.10.2011
Subjects:	Adult Anticoagulants - antagonists & inhibitors Antidotes - pharmacology Benzimidazoles - antagonists & inhibitors beta-Alanine - analogs & derivatives beta-Alanine - antagonists & inhibitors Blood Coagulation - drug effects Blood Coagulation Factors - pharmacology Cross-Over Studies Dabigatran Double-Blind Method Endopeptidases Factor Xa Inhibitors Humans Male Morpholines - antagonists & inhibitors Partial Thromboplastin Time Prothrombin Time Rivaroxaban Thiophenes - antagonists & inhibitors Thrombin - antagonists & inhibitors Thrombin Time Young Adult
ISSN:	1524-4539, 1524-4539
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!